公司新闻－重庆睿仕康生物医药有限公司

Home
Ruishikang
- About Ruishikang
  - Company Profile
    Jointly Creating a Healthy China
  - Corporate Culture
    Listen to the voice of the CEO
- Development History
  - Honor and Qualification
    Sustainable Development
  - Memorabilia
    Excellent Corporate Citizen
- Ruishikang Global
  - Expert Advisor
    Leadership in China Business
  - Core Team
    The top leadership of the company
Product
R&D
- Research and Development Platform
- R&D Pipeline
News
- Industry News
- Ruishikang News

Contact Us 中文 EN

Ruiyi Enterprising
- Focus Areas
  - Tumor
    Ruiyi Enterprising Together to Cure Cancer
  - Vaccinum
    Vaccines make health within reach
  - Anti-Infection
    Strive for AI comprehensively
  - Inflammation and immunity
    Ruiyi Enterprising and Revitalizing
  - Rare Disease
    Rui Yi Enterprising for Love and Care
- Ruishikang China R&D Center
  - 研发中心 |上海
  - 研发中心 |武汉
- Product pipeline
Innovative Product
- Product List
- Medical Information
News Center
- Company News
- Ruishikang Annual Report
About Ruishikang
- Ruishikang Global
  - Global Overview
    Ruiyi Enterprising
  - Management team
    The highest leadership of the company
- Ruishikang China
  - Overview of Ruishikang
    Jointly Creating a Healthy China
  - Message from the President
    Listen to the voice of the CEO
- 责任
  - Corporate Governance
    Sustainable Development
  - Corporate Responsibility
    Excellent Corporate Citizen
- Career Development
  - Talent recruitment

中文 / EN

Home Page News Center Company News Ruishikang's research and development of new stem cell drugs for rheumatoid arthritis has entered th

Ruishikang's research and development of new stem cell drugs for rheumatoid arthritis has entered th

2024-01-31

Ruishikang's research and development of new stem cell drugs for rheumatoid arthritis has entered the clinical stage